Celyad gets the go-ahead to resume CAR-T trial for colorectal cancer as FDA lifts hold
Four months ago, the FDA placed a clinical hold on Celyad’s CAR-T trial for colorectal cancer after two patients died during the study. Regulators have …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
